Significantly Improved Nasal Congestion/Obstruction Score at
Weeks 24 (Coprimary Endpoint) and 52 (Key Secondary Endpoint) in Patients Who Were Uncontrolled on SOC1,2,a

SINUS-52

CHANGE IN NC SCORE THROUGH WEEK 52

51%

IMPROVEMENT AT WEEK 24 with DUPIXENT Q2W + INCS (n=295, pooled DUPIXENT arms) (-1.25 from a baseline score of 2.46) vs 16% improvement with placebo + INCS (n=153) (-0.38 from a baseline score of 2.38) (LSM difference: -0.87 [95% CI: -1.03, -0.71]) in SINUS-521

  • NC SCORE IMPROVED AS EARLY AS WEEK 4 IN SINUS-52: -0.52 with DUPIXENT Q2W + INCS (n=295, pooled DUPIXENT arms) vs -0.16 with placebo + INCS (n=153) (LSM difference: -0.37 [95% CI: -0.46, -0.27])1,2
59%

IMPROVEMENT AT WEEK 24 with DUPIXENT Q2W + INCS (-1.34 from a baseline score of 2.26) vs 18% improvement with placebo + INCS (-0.45 from a baseline score of 2.45) (LSM difference: -0.89 [95% CI: -1.07, -0.71]) in SINUS-241

a All patients in the placebo and DUPIXENT arms were on a background therapy of INCS, mometasone furoate nasal spray.1

Nasal congestion/obstruction (NC) score (range 0 to 3): reduced score indicates improvement.

see scs use + sino-nasal surgery results
Back to sense of smell

Explore the Safety Data
and Study Designs

VIEW safety data SEE THE FULL STUDY DESIGNS

Dosage and
Administration
See the recommended dosing and administration options for patients
on DUPIXENT.
Explore ADMINISTRATION Options